Halobetasol propionate is a synthetic, high-potency (Class I) topical corticosteroid. It is a difluorinated derivative of clobetasol propionate, exhibiting potent anti-inflammatory, antipruritic, and vasoconstrictive properties. It is primarily used for short-term treatment of severe, recalcitrant corticosteroid-responsive dermatoses where less potent steroids have failed. In the Indian context, it is a critical tool for managing severe inflammatory skin conditions, but its use is strictly regulated due to high potency and significant risk of local and systemic adverse effects.
Adult: Apply a thin film to the affected area once or twice daily. Rub in gently. Treatment should be limited to 2 consecutive weeks. Maximum weekly dose: 50 grams.
Note: 1. Wash and dry the affected area. 2. Apply a thin layer only to the affected skin. 3. Do not bandage, wrap, or cover the area (occlude) unless directed by a physician. 4. Avoid contact with eyes, mouth, nose, and mucous membranes. 5. Wash hands after application unless hands are the treatment area. 6. Do not use on broken or infected skin unless infection is being treated concurrently with appropriate antimicrobials.
Halobetasol propionate binds with high affinity to the cytosolic glucocorticoid receptor (GR). The drug-receptor complex translocates to the nucleus, where it modulates gene transcription. It induces the synthesis of anti-inflammatory proteins (like lipocortin-1) and inhibits the synthesis of pro-inflammatory mediators (such as prostaglandins, leukotrienes, IL-1, IL-2, TNF-α). It also suppresses the migration of polymorphonuclear leukocytes and reverses capillary permeability.
Pregnancy: US FDA Pregnancy Category C. Animal studies show teratogenicity. No adequate, well-controlled studies in pregnant women. Should be used only if the potential benefit justifies the potential risk to the fetus. Use the minimum amount for the shortest time. Avoid large areas or prolonged use.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic adverse effects, including HPA axis suppression. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | May inhibit the metabolism of systemically absorbed halobetasol, increasing the risk of systemic corticosteroid effects. | Moderate |
| Live Vaccines (e.g., BCG, MMR, Varicella) | Topical corticosteroids, especially potent ones, may potentiate replication of vaccine virus, increase risk of vaccine-induced infection, and impair antibody response. Avoid vaccination during treatment. | Major |